JP2017501235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501235A5 JP2017501235A5 JP2016562082A JP2016562082A JP2017501235A5 JP 2017501235 A5 JP2017501235 A5 JP 2017501235A5 JP 2016562082 A JP2016562082 A JP 2016562082A JP 2016562082 A JP2016562082 A JP 2016562082A JP 2017501235 A5 JP2017501235 A5 JP 2017501235A5
- Authority
- JP
- Japan
- Prior art keywords
- iron
- iii
- torimarutoru
- formulation
- elemental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 206010022971 Iron Deficiencies Diseases 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 208000007502 anemia Diseases 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000021152 breakfast Nutrition 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 229960001021 lactose monohydrate Drugs 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 20
- 238000002360 preparation method Methods 0.000 claims 4
- 229940082629 iron antianemic preparations Drugs 0.000 claims 2
- 239000007963 capsule composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1400171.3 | 2014-01-06 | ||
| GB201400171A GB201400171D0 (en) | 2014-01-06 | 2014-01-06 | Dosage regimen |
| GB1418708.2 | 2014-10-21 | ||
| GB201418708A GB201418708D0 (en) | 2014-10-21 | 2014-10-21 | Dosage regimen |
| PCT/IB2015/050098 WO2015101971A1 (en) | 2014-01-06 | 2015-01-06 | Dosage regimen of ferric trimaltol |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019072643A Division JP2019131592A (ja) | 2014-01-06 | 2019-04-05 | トリマルトール鉄（ｉｉｉ）の投与計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501235A JP2017501235A (ja) | 2017-01-12 |
| JP2017501235A5 true JP2017501235A5 (enExample) | 2017-09-28 |
| JP6556753B2 JP6556753B2 (ja) | 2019-08-07 |
Family
ID=52432872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562082A Active JP6556753B2 (ja) | 2014-01-06 | 2015-01-06 | トリマルトール鉄（ｉｉｉ）の投与計画 |
| JP2019072643A Withdrawn JP2019131592A (ja) | 2014-01-06 | 2019-04-05 | トリマルトール鉄（ｉｉｉ）の投与計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019072643A Withdrawn JP2019131592A (ja) | 2014-01-06 | 2019-04-05 | トリマルトール鉄（ｉｉｉ）の投与計画 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179120B2 (enExample) |
| EP (1) | EP3091974B1 (enExample) |
| JP (2) | JP6556753B2 (enExample) |
| KR (1) | KR102351422B1 (enExample) |
| CN (2) | CN106413706A (enExample) |
| AU (1) | AU2015204192B2 (enExample) |
| BR (1) | BR112016015766A2 (enExample) |
| CA (1) | CA2934836C (enExample) |
| ES (1) | ES2785391T3 (enExample) |
| IL (1) | IL246613B (enExample) |
| SI (1) | SI3091974T1 (enExample) |
| WO (1) | WO2015101971A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2785391T3 (es) | 2014-01-06 | 2020-10-06 | Shield Tx Uk Ltd | Régimen de dosificación de trimaltol férrico |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
| CN109071481B (zh) | 2016-03-31 | 2022-09-30 | 英国神盾Tx股份有限公司 | 用于由元素铁产生麦芽酚铁组合物的方法 |
| CN109310667B (zh) * | 2016-03-31 | 2022-01-11 | 英国神盾Tx股份有限公司 | 用于治疗或预防癌症和肿瘤的麦芽酚铁组合物 |
| AU2017242901B2 (en) * | 2016-03-31 | 2020-11-19 | Shield TX (UK) Limited | Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides |
| CN109311837B (zh) | 2016-03-31 | 2022-09-30 | 英国神盾Tx股份有限公司 | 用于由氢氧化亚铁产生麦芽酚铁组合物的方法 |
| GB2553099A (en) * | 2016-08-19 | 2018-02-28 | Shield Tx Uk Ltd | Use |
| IT202100018578A1 (it) * | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1150213B (it) * | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| SU1676626A1 (ru) * | 1989-05-17 | 1991-09-15 | Тюменский государственный медицинский институт | Способ лечени железодефицитных анемий |
| RO113611B1 (ro) * | 1990-08-03 | 1998-09-30 | Asta Pharma Ag | Preparate solide de ifosfamida, administrate oral si procedeu de obtinere |
| DE69633178T2 (de) | 1995-06-10 | 2005-08-11 | Vitra Pharmaceuticals Ltd., Saffron Walden | Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| ES2236300T3 (es) | 2000-09-19 | 2005-07-16 | Vitra Pharmaceuticals Ltd. | Composiciones de hierro. |
| US20050118291A1 (en) * | 2003-09-10 | 2005-06-02 | Mian-Ying Wang | Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane |
| US20070087036A1 (en) * | 2005-05-03 | 2007-04-19 | Durschlag Maurice E | Edible film for transmucosal delivery of nutritional supplements |
| EP1757299A1 (de) * | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
| US20070111936A1 (en) * | 2005-11-15 | 2007-05-17 | Vladimir Pak | Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| GB0808835D0 (en) | 2008-05-15 | 2008-06-18 | Vitra Pharmaceuticals Ltd | Therapeutic compositions |
| GB201101370D0 (en) * | 2011-01-27 | 2011-03-09 | Iron Therapeutics Holdings Ag | Process |
| JP5856725B2 (ja) * | 2011-08-02 | 2016-02-10 | 和夫 酒井 | うつ病治療用または予防用医薬組成物 |
| ES2785391T3 (es) | 2014-01-06 | 2020-10-06 | Shield Tx Uk Ltd | Régimen de dosificación de trimaltol férrico |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
-
2015
- 2015-01-06 ES ES15701588T patent/ES2785391T3/es active Active
- 2015-01-06 CA CA2934836A patent/CA2934836C/en active Active
- 2015-01-06 JP JP2016562082A patent/JP6556753B2/ja active Active
- 2015-01-06 BR BR112016015766A patent/BR112016015766A2/pt not_active Application Discontinuation
- 2015-01-06 KR KR1020167021033A patent/KR102351422B1/ko active Active
- 2015-01-06 EP EP15701588.4A patent/EP3091974B1/en active Active
- 2015-01-06 CN CN201580005412.7A patent/CN106413706A/zh active Pending
- 2015-01-06 WO PCT/IB2015/050098 patent/WO2015101971A1/en not_active Ceased
- 2015-01-06 CN CN202111268204.XA patent/CN114010629A/zh active Pending
- 2015-01-06 SI SI201531165T patent/SI3091974T1/sl unknown
- 2015-01-06 US US15/110,003 patent/US10179120B2/en active Active
- 2015-01-06 AU AU2015204192A patent/AU2015204192B2/en active Active
-
2016
- 2016-07-05 IL IL246613A patent/IL246613B/en active IP Right Grant
-
2019
- 2019-04-05 JP JP2019072643A patent/JP2019131592A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501235A5 (enExample) | ||
| JP2011509295A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| IL298998B2 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| JP2009529502A5 (enExample) | ||
| JP2012533565A5 (enExample) | ||
| RU2015138708A (ru) | Фармацевтические композиции для лечения от helicobacter pylori | |
| JP2014518274A5 (enExample) | ||
| JP2019529570A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2016505050A5 (enExample) | ||
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| JP2019507786A5 (enExample) | ||
| JPWO2018193752A1 (ja) | アルカリ性化剤による血液浄化 | |
| JP2016512493A5 (enExample) | ||
| JP2019509309A5 (enExample) | ||
| JP2013544795A5 (enExample) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| MX2010011193A (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor. | |
| JP2019533672A5 (enExample) | ||
| Garnock-Jones | Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine | |
| XIAO | A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for# br# mild-to-moderate Alzheimer disease | |
| JP2015509934A5 (enExample) |